How much has Pathos raised?

Pathos has raised $237M in one sourced round on record (Series B+), announced October 23, 2026.

Who invested in Pathos?

Investors on record for Pathos: Bristol-Myers Squibb, Builders VC, NEA and Revolution Growth. Bristol-Myers Squibb led its latest sourced round.

Pathos was founded by Eric Lefkofsky and Ryan Fukushima.

Where is Pathos based?

Pathos is based in New York, United States.

Pathos

Pathos is a biotechnology company that leverages AI to accelerate oncology drug development.

Health and bio

Latest funding

$237M Series B+ · October 23, 2026

Led by Bristol-Myers Squibb · Source: axios.com

Funding history ↓

Website: pathos.com.

LinkedIn: linkedin.com.

Category: Health and bio.

Sectors: Artificial Intelligence (AI), Biotechnology, Data Management, Life Science, Medical.

Stage: Series B+.

Based in: New York, United States.

Last round: Oct 23, 2026 · 1 days ago.

On Recent Funding since: Oct 24, 2026.

About Pathos

Pathos is a company based in New York, United States. Recent Funding lists it under Health and bio. It raised $237M in a Series B+ round in October 2026, led by Bristol-Myers Squibb, according to axios.com. Investors on record include Builders VC, NEA and Revolution Growth. It was founded by Eric Lefkofsky and Ryan Fukushima. It has acquired 2 companies on record, most recently DeuterOncology (May 2026).

Funding rounds

October 23, 2026
Series B+ · $237M
BBristol-Myers Squibb (lead)
Source: axios.com

Founders and team

EL
Eric Lefkofsky Founder
RF
Ryan Fukushima Founder
IH
Iker Huerga Chief Executive Officer

Acquisitions

Acquired company	Price	Announced
DDeuterOncology	Not disclosed	May 6, 2026 · Yahoo Finance
RRain Oncology	Not disclosed publicly	Date not given

Investors

Similar Health and bio companies

HHexagon Bio$62M Series B+ · Oct 2026
BBioStack$9.5M Seed · Oct 2026
HHeyVoli$500K Pre Seed · Oct 2026
VVitalls$1.5M Seed · Oct 2026
SStar Therapeutics$200M Series B+ · Oct 2026
WWarp Sciences$215M Series A · Oct 2026

Other companies backed by Bristol-Myers Squibb

GGlycoEra$130M Series B+ · May 2025
AAkamis Bio$60M Series A · Dec 2024
EEnvisagenics$25M Series B+ · Jun 2024
AAsher Bio$55M Series B+ · Apr 2024
AAccent Therapeutics$75M Series B+ · Jan 2024
KK36 Therapeutics$70M Series B+ · Jun 2023

Bristol-Myers Squibb portfolio →

Questions and sources

Pathos: questions and answers

How much has Pathos raised?: Pathos has raised $237M in one sourced round on record (Series B+), announced October 23, 2026.
Who invested in Pathos?: Investors on record for Pathos: Bristol-Myers Squibb, Builders VC, NEA and Revolution Growth. Bristol-Myers Squibb led its latest sourced round.
Who founded Pathos?: Pathos was founded by Eric Lefkofsky and Ryan Fukushima.
Where is Pathos based?: Pathos is based in New York, United States.

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/pathos (get a free API key).